Scott Solomon, M.D.

<<Back To Our Physicians

Dr. Scott Solomon
Castle Connelly Top Doctors 2024

Scott Solomon, M.D., is board certified in the subspecialties of medical oncology and hematology. He is the Medical Director of the Northside Hospital Blood and Marrow Transplant Matched Unrelated Donor Program and the Medical Director of the Northside Hospital Stem Cell Processing Laboratory. Dr. Solomon is also a Northside Hospital Leukemia and Immunotherapy Program physician. Dr. Solomon has been Atlanta's Top Doctor in his specialty from 2013 to 2024.

Training

  • University of Virginia, Echols Scholar and a member of Phi Beta Kappa Honor Society

  • M.D., Alpha Omega Alpha Honor Society, University of Maryland School of Medicine

    • Participated in highly competitive Howard Hughes Medical Institute (HHMI)- NIH Research Scholars Program

    • Received the Medical Student Research Award from the American Federation for Clinical Research

  • Fellowship: Hematology-Oncology, University of California, San Francisco

  • Fellowship: Blood and Marrow Transplant, University of California, San Francisco and NHLBI/NIH

Society Memberships

  • American Society of Clinical Oncology

  • American Society of Hematology

  • American Society for Blood and Marrow Transplantation

Past Academic Faculty Appointments

  • National Institutes of Health (NIH), National Heart, Lung and Blood Institute (NHLBI), Bethesda, Maryland

Publications

  • Authored and co-authored more than 230 research articles and abstracts in peer-reviewed journals: Blood, Journal of Clinical Oncology, Biology of Blood and Marrow Transplantation, Bone Marrow Transplantation, and the British Journal of Hematology

Dr. Solomon’s clinical and translational research interests include novel approaches to treating leukemia, lymphoma, and myeloma. More specifically, his work has focused on the role of allogeneic and autologous immune system modulation in treating various blood cancers. Past and current trials evaluate the role of haploidentical transplantation, CAR-T therapy, immune checkpoint inhibitors and adoptive immunotherapy. In addition, another interest of Dr. Solomon’s involves improving the success of allogeneic stem cell transplantation, with an emphasis on developing novel graft-versus-host disease (GVHD) prevention and treatment strategies.